Antengene appoints Bing Hou as chief scientific officer

• Antengene appointed Bing Hou as chief scientific officer on May 19, 2026, reporting to founder, chairman and CEO Jay Mei.
• Hou will lead drug discovery, translational medicine, and chemistry, manufacturing and controls, with a mandate to deepen internal R&D and build a next-generation pipeline.
• He joined Antengene in 2019, most recently serving as vice president and head of discovery science and translational medicine, where he built the discovery organization and advanced internally discovered programs into clinical development.
• Hou holds a PhD in biomedicine from the University of Leeds and has published in journals including Nature and Science Advances, with more than 40 patent applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605192000PR_NEWS_USPR_____CN62873) on May 20, 2026, and is solely responsible for the information contained therein.